Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INP 20

Next Previous
Drug Profile

INP 20

Alternative Names: INP20; Peanut allergy immunotherapy - InnoUp Farma

Latest Information Update: 01 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator InnoUp Farma
  • Class Allergens; Antiallergics; Food allergy immunotherapies; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Peanut hypersensitivity

Most Recent Events

  • 23 Feb 2024 Interim adverse events data from a phase I/II clinical trials in Peanut hypersensitivity presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI-2024)
  • 06 Mar 2020 Phase-I/II clinical trials in Peanut hypersensitivity (In children, In adolescents, In adults, In the elderly) in Spain (PO) (NCT04163562)
  • 21 Nov 2019 The Spanish Agency of Medicines and Health Products approves clinical trial application for a phase I/II trial in Peanut hypersensitivity (In children, In adolescents, In adults, In the elderly) (PO) (InnoUp Farma website, November 2019).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top